A 12 Week, Double-Blind, Randomized, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg Compared to Aliskiren 300 mg in Patients With Stage II Hypertension.
Phase of Trial: Phase III
Latest Information Update: 02 May 2016
At a glance
- Drugs Aliskiren; Aliskiren/hydrochlorothiazide
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Acronyms ACQUIRE
- Sponsors Novartis
- 01 Aug 2012 Results published in the Journal of Clinical Hypertension (Greenwich).
- 22 Jan 2010 Actual end date (April 2009) added as reported by ClinicalTrials.gov.
- 22 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History